Skeletal metastases in non-small cell lung cancer: a retrospective study

A Tsuya, T Kurata, K Tamura, M Fukuoka - Lung cancer, 2007 - Elsevier
BACKGROUND: The skeleton is one of the most common sites of metastasis in patients with
advanced cancer. Bone metastases often cause SREs (skeletal-related events). Despite …

[HTML][HTML] Prognostic impact of circulating tumor cells in patients with small cell lung cancer

…, H Murakami, Y Nakamura, A Tsuya… - Journal of Thoracic …, 2012 - Elsevier
Background Enumeration of circulating tumor cells (CTCs) may be valuable for prognostic
assessment in lung cancer patients. In this study, we report the clinical significance of CTCs in …

[HTML][HTML] Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system

…, T Takahashi, H Murakami, Y Nakamura, A Tsuya… - PloS one, 2013 - journals.plos.org
Background Epithelial cell adhesion molecule (EpCAM)-based enumeration of circulating
tumor cells (CTC) has prognostic value in patients with solid tumors, such as advanced breast, …

[HTML][HTML] The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer

…, A Ono, T Shukuya, Y Nakamura, A Tsuya… - Journal of Thoracic …, 2011 - Elsevier
Introduction It is unknown what type of interstitial lung disease (ILD) has high risk for
chemotherapy-related exacerbation of ILD. We investigated the risk of exacerbation of ILD for …

Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors

…, I Okamoto, M Miyazaki, R Morinaga, A Tsuya… - Clinical Cancer …, 2009 - AACR
Purpose: YM155, a novel molecular targeted agent, suppresses survivin, a member of the
inhibitor of apoptosis protein family that is overexpressed in many tumor types. The aim of this …

Efficacy of gefitinib for non‐adenocarcinoma non‐small‐cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of …

…, R Kaira, A Ono, Y Nakamura, A Tsuya… - Cancer …, 2011 - Wiley Online Library
The efficacy of gefitinib for patients with non‐adenocarcinoma non‐small‐cell lung cancer (NSCLC)
harboring epidermal growth factor receptor (EGFR) mutations is unclear, because …

[PDF][PDF] Biologic Correlation of 2-[18F]-Fluoro-2-Deoxy-D-Glucose Uptake on Positron Emission Tomography in Thymic Epithelial Tumors

…, T Takahashi, H Murakami, A Tsuya… - Journal of clinical …, 2010 - researchgate.net
Purpose The usefulness of 2-[18F]-fluoro-2-deoxy-D-glucose ([18F] FDG) positron emission
tomography (PET) can help predict the grade of malignancy and staging in thymic epithelial …

[HTML][HTML] Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis

…, E Ayabe, H Murakami, T Takahashi, A Tsuya… - Journal of Thoracic …, 2010 - Elsevier
Background Pulmonary pleomorphic carcinoma is a rare epithelial tumor and has an
aggressive clinical course. As few studies of pulmonary pleomorphic carcinoma have been …

HER3 augmentation via blockade of EGFR/AKT signaling enhances anticancer activity of HER3-targeting patritumab deruxtecan in EGFR-mutated non–small cell lung …

…, K Tanaka, H Hayashi, K Sakai, Y Chiba, A Tsuya… - Clinical Cancer …, 2022 - AACR
Purpose: EGFR-tyrosine kinase inhibitor (TKI) is a standard first-line therapy for activated
EGFR-mutated non–small cell lung cancer (NSCLC). Treatment options for patients with …

Utility of 18FDG-PET for differentiating the grade of malignancy in thymic epithelial tumors

…, T Okumura, H Kondo, S Igawa, Y Nakamura, A Tsuya… - Lung Cancer, 2008 - Elsevier
PURPOSE: The objective of this study was to assess the value of 18 F-FDG PET in thymic
epithelial tumors according to the WHO histologic classification and to evaluate its potential for …